Anlotinib (BioDeep_00000016503)
代谢物信息卡片
Anlotinib
化学式: C23H22FN3O3 (407.1645)
中文名称: 1-[[[4-[(4-氟-2-甲基-1H-吲哚-5-基)氧基]-6-甲氧基-7-喹啉基]氧基]甲基]环丙胺
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC
InChI: InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- KEGG: C13643
- PubChem: 25017411
- DrugBank: DB11885
- ChEMBL: CHEMBL4303201
- CAS: 1058156-90-3
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Gang Tan, Guanghui Hou, Junmin Qian, Yaping Wang, Weijun Xu, Wenjuan Luo, Xiaobing Chen, Aili Suo. Hyaluronan-decorated copper-doxorubicin-anlotinib nanoconjugate for targeted synergistic chemo/chemodynamic/antiangiogenic tritherapy against hepatocellular carcinoma.
Journal of colloid and interface science.
2024 May; 662(?):857-869. doi:
10.1016/j.jcis.2024.02.085. [PMID: 38382370] - Xingxiang Pu, Zemin Xiao, Jia Li, Zhijun Wu, Zhongxia Ma, Jie Weng, Maoliang Xiao, Yanhua Chen, Yongqing Cao, Peiguo Cao, Qianzhi Wang, Yan Xu, Kang Li, Bolin Chen, Fang Xu, Liyu Liu, Yi Kong, Hui Zhang, Huaxin Duan, Lin Wu. Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial.
Lung cancer (Amsterdam, Netherlands).
2024 May; 191(?):107538. doi:
10.1016/j.lungcan.2024.107538. [PMID: 38552544] - Li-Huai Wang, Yin-Hui Sun, Hua Liu, Xiao Yang, Zhi Wen, Xue-Fei Tian. β-Sitosterol attenuates anlotinib resistance in non-small cell lung cancer cells by inhibiting miR-181a-3p/SHQ1 signaling.
Chemical biology & drug design.
2024 03; 103(3):e14493. doi:
10.1111/cbdd.14493. [PMID: 38439529] - Li Liu, Shuo Zhang, Hai-Yan Yang, Chun-Hua Zhou, Yi Xiong, Nong Yang, Ye Tian. Lipid alterations play a role in the integration of PD-1/PD-L1 inhibitors and anlotinib for the treatment of advanced non-small-cell lung cancer.
Lipids in health and disease.
2024 Jan; 23(1):16. doi:
10.1186/s12944-023-01960-7. [PMID: 38218878] - Xin Qiu, Changchang Lu, Huizi Sha, Yahui Zhu, Weiwei Kong, Fan Tong, Qiaoli Wang, Fanyan Meng, Baorui Liu, Juan Du. Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial.
Frontiers in immunology.
2024; 15(?):1210859. doi:
10.3389/fimmu.2024.1210859. [PMID: 38361920] - Xue Wu, Lili Qiao, Tiantian Tian, Yang Shu, Yingying Zhang. Orbital adenoid cystic carcinoma treated by radiotherapy combined with anlotinib in a 13-year-old girl: A case report.
Medicine.
2023 Sep; 102(35):e34544. doi:
10.1097/md.0000000000034544. [PMID: 37657046] - Zhongling Zhu, Shan Xu, Jing Ren, Teng Jiang, Cai Zhang, Zhao Yan. Anlotinib affects systemic lipid metabolism and induces lipid accumulation in human lung cancer cells.
Lipids in health and disease.
2023 Aug; 22(1):134. doi:
10.1186/s12944-023-01907-y. [PMID: 37612751] - Yingying Shi, Zhuolun Li, Qiuzheng Du, Wenxi Li, Jiyun Liu, Qingquan Jia, Lianping Xue, Xiaojian Zhang, Zhi Sun. UHPLC-HRMS-based metabolomic and lipidomic characterization of glioma cells in response to anlotinib.
Scientific reports.
2023 05; 13(1):8044. doi:
10.1038/s41598-023-34902-5. [PMID: 37198251] - Na Wang, Lu Zhao, Dou Zhang, Fanming Kong. Efficacy and safety of anlotinib as maintenance therapy after induction chemotherapy in extensive-stage small-cell lung cancer.
Anti-cancer drugs.
2023 04; 34(4):558-562. doi:
10.1097/cad.0000000000001488. [PMID: 36728981] - Shumin Yuan, Ling Peng, Yuqing Liu, Brian G Till, Xiang Yan, Jie Zhang, Liping Zhu, Huijuan Wang, Shaokai Zhang, Hongle Li, Quanli Gao, Zibing Wang. Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients.
Cancer immunology, immunotherapy : CII.
2023 Feb; 72(2):437-448. doi:
10.1007/s00262-022-03259-5. [PMID: 35931835] - Wenmin Chen, Jietao Lin, Ting Yang, Ze Xin Zhang, Lanting Tao, Zhiwei Xiao, Hanrui Chen, Xiangjun Qi, Lingling Sun, Yang Cao, Lizhu Lin. Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study.
Integrative cancer therapies.
2023 Jan; 22(?):15347354221151147. doi:
10.1177/15347354221151147. [PMID: 36710490] - Aimi Huang, Weimin Wang, Ruoyan Qin, Guojie Chen, Aiqin Gu, Baohui Han. Efficacy, safety, and prognostic factors of anlotinib treatment in advanced non-small cell lung cancer patients.
Journal of cancer research and therapeutics.
2022 Sep; 18(5):1299-1305. doi:
10.4103/jcrt.jcrt_835_21. [PMID: 36204876] - Jie Li, Peiyu Cao, Yuxin Chen, Junqi Wang, Xiaolei Sun, Renfu Chen, Gang Wang, Jianquan Hou. Anlotinib combined with the PD-L1 blockade exerts the potent anti-tumor immunity in renal cancer treatment.
Experimental cell research.
2022 Aug; 417(1):113197. doi:
10.1016/j.yexcr.2022.113197. [PMID: 35568074] - Bo Cao, Shiyuan Wang, Ruisheng Li, Zhihong Wang, Taifeng Li, Yuanyuan Zhang, Bin Dong, Yingying Li, Mengmeng Lin, Xingjie Li, Xiaohe Xiao, Chunyu Li, Guohui Li. Xihuang Pill enhances anticancer effect of anlotinib by regulating gut microbiota composition and tumor angiogenesis pathway.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2022 Jul; 151(?):113081. doi:
10.1016/j.biopha.2022.113081. [PMID: 35605293] - Shasha Wang, Ning Lou, Rongrong Luo, Xuezhi Hao, Yutao Liu, Lin Wang, Yuankai Shi, Xiaohong Han. Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC.
Journal of translational medicine.
2022 05; 20(1):248. doi:
10.1186/s12967-022-03451-2. [PMID: 35642002] - Zhiping Jin, Qingfeng He, Xiao Zhu, Mingshe Zhu, Yike Wang, Xin-An Wu, Qianzhou Lv, Xiaoqiang Xiang. Application of physiologically based pharmacokinetic modelling for the prediction of drug-drug interactions involving anlotinib as a perpetrator of cytochrome P450 enzymes.
Basic & clinical pharmacology & toxicology.
2022 May; 130(5):592-605. doi:
10.1111/bcpt.13721. [PMID: 35289081] - Dou Yang, Feng Chen, Dan Gong, Lei Zeng, Deng Xiang, Yuanqiao He, Leifeng Chen, Jinlong Yan, Shouhua Zhang. Establishment of childhood hepatoblastoma xenografts and evaluation of the anti-tumour effects of anlotinib, oxaliplatin and sorafenib.
Pediatric surgery international.
2022 Mar; 38(3):465-472. doi:
10.1007/s00383-021-05043-5. [PMID: 35032209] - Yuqi Jiang, Lei Zhang, Fuyun Zhu, Hui Zhu, Xiaowen Cao, Yongchun Zhang. Camrelizumab combined with anlotinib for the treatment of small cell lung cancer: a case report and literature review.
Annals of palliative medicine.
2022 Mar; 11(3):1135-1146. doi:
10.21037/apm-21-3860. [PMID: 35365044] - Ping Du, Lingling Xuan, Ting Hu, Zhuoling An, Lihong Liu. Serum Eicosanoids Metabolomics Profile in a Mouse Model of Renal Cell Carcinoma: Predicting the Antitumor Efficacy of Anlotinib.
Frontiers in immunology.
2022; 13(?):824607. doi:
10.3389/fimmu.2022.824607. [PMID: 35222406] - Xiao-Qi Chen, Yun-Xia Zhao, Chuan-Lei Zhang, Xin-Ting Wang, Xin Zhang, Xi Chen, Chang-Wei Yuan, Qing Zhao, Xin-Ju Chen. Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in the Treatment of Patients with Advanced Primary Hepatocellular Carcinoma: A Retrospective, Real-World Study in China.
Drug design, development and therapy.
2022; 16(?):1483-1493. doi:
10.2147/dddt.s358092. [PMID: 35607597] - Zhijun Li, Haisheng Chen, Jing Shi, Feng Wang, Yuguo Liu. A novel method for the quantification of anlotinib in human plasma using two-dimensional liquid chromatography.
Biomedical chromatography : BMC.
2021 Dec; 35(12):e5218. doi:
10.1002/bmc.5218. [PMID: 34291843] - Mengqiu Tang, Chao Song, Yaowen Zhang, Xiaoyu Xu, Chen Wang, Zhanchun Zhang, Tian Chen. Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib.
Lipids in health and disease.
2021 Nov; 20(1):165. doi:
10.1186/s12944-021-01596-5. [PMID: 34801029] - Yongkun Sun, Aiping Zhou, Wen Zhang, Zhichao Jiang, Bo Chen, Jianjun Zhao, Zhiyu Li, Liming Wang, Xinyu Bi, Hong Zhao, Kan Liu. Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study).
Hepatology international.
2021 Jun; 15(3):621-629. doi:
10.1007/s12072-021-10171-0. [PMID: 33826043] - Zhuohong Li, Juncai Tian, Lei Du, Ying Gao, Yao Wang, Fengming You, Li Wang. Anlotinib exerts anti-cancer efficiency on lung cancer stem cells in vitro and in vivo through reducing NF-κB activity.
Journal of cellular and molecular medicine.
2021 06; 25(12):5547-5559. doi:
10.1111/jcmm.16564. [PMID: 33955683] - Song Peng, Wenhong Dong, Qiangqiang Chu, Jia Meng, Haitao Yang, Yingying DU, Y U Sun, Robert M Hoffman. Traditional Chinese Medicine Brucea Javanica Oil Enhances the Efficacy of Anlotinib in a Mouse Model of Liver-Metastasis of Small-cell Lung Cancer.
In vivo (Athens, Greece).
2021 May; 35(3):1437-1441. doi:
10.21873/invivo.12395. [PMID: 33910820] - Qiong Luo, Suyun Zhang, Donghuan Zhang, Rui Feng, Nan Li, Wujin Chen, Xiangqi Chen, Sheng Yang. Effects and Mechanisms of Anlotinib and Dihydroartemisinin Combination Therapy in Ameliorating Malignant Biological Behavior of Gastric Cancer Cells.
Current pharmaceutical biotechnology.
2021; 22(4):523-533. doi:
10.2174/1389201021666200623132803. [PMID: 32576126] - Weilan Lan, Jinyan Zhao, Wujin Chen, Haixia Shang, Jun Peng, Jiumao Lin. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
Anti-cancer agents in medicinal chemistry.
2021; 21(15):1987-1995. doi:
10.2174/1871520621666210112113852. [PMID: 33438566] - Shuo Li, Linping Ke, Xue Meng, Haiyan Zhou, Xiqin Zhang, Huaguo Wu, Jinming Yu, Hui Zhang. Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review.
Recent patents on anti-cancer drug discovery.
2021; 16(1):108-116. doi:
10.2174/1574892815666201127114224. [PMID: 33245275] - Yinhua Wang, Xiuhua Shi, Qinghua Qi, Bin Ye, Zhaoling Zou. Safety of Anlotinib Capsules Combined with PD-1 Inhibitor Camrelizumab in the Third-Line Treatment of Advanced Non-Small-Cell Lung Cancer and Their Effect on Serum Tumor Markers.
Journal of healthcare engineering.
2021; 2021(?):2338800. doi:
10.1155/2021/2338800. [PMID: 34956561] - Guoqing Gu, Chenxi Hu, Kaiyuan Hui, Huiqin Zhang, Ting Chen, Xin Zhang, Xiaodong Jiang. Exosomal miR-136-5p Derived from Anlotinib-Resistant NSCLC Cells Confers Anlotinib Resistance in Non-Small Cell Lung Cancer Through Targeting PPP2R2A.
International journal of nanomedicine.
2021; 16(?):6329-6343. doi:
10.2147/ijn.s321720. [PMID: 34556984] - Feilong He, Qi Bao, Jiangtao Bai, Jianping Wang, Jianglong Zhai, Qiquan Yu, Wentao Guo, Chunxiao Wu, Kun Zhang, Weizhen Shou, Guoying Zhu. Effects of I-125 seeds combined with anlotinib on tumor growth and bone metabolism in A549 tumor-bearing mice.
International journal of radiation biology.
2021; 97(11):1578-1588. doi:
10.1080/09553002.2021.1976860. [PMID: 34491151] - Ying Zhang, Beili Jia, Jing Li, Xiaomei Xu. Anlotinib in treatment of an elderly patient with recurrent advanced SCLC.
Tumori.
2020 Dec; 106(6):NP36-NP40. doi:
10.1177/0300891619900673. [PMID: 32031060] - Feng Gao, Xiaofeng Cong, Ziling Liu. Successful treatment of a patient with small cell lung cancer receiving hemodialysis, with concurrent oral etoposide and radiotherapy: A case report.
Medicine.
2020 Oct; 99(40):e22637. doi:
10.1097/md.0000000000022637. [PMID: 33019486] - Y Song, Chi Yihebali, L Yang, C X Cui, W Zhang, Y K Sun, C X Du, A P Zhou, J W Wang. [Long term follow-up results of anlotinib in the treatment of advanced renal cell carcinoma].
Zhonghua zhong liu za zhi [Chinese journal of oncology].
2020 Sep; 42(9):765-770. doi:
10.3760/cma.j.cn112152-20200214-00089. [PMID: 32988160] - Ping Du, Ting Hu, Zhuoling An, Pengfei Li, Lihong Liu. Simultaneous quantitative determination of arachidonic acid and cascade metabolites in rat serum by UPLC-MS/MS: application for longitudinal metabolomics of anlotinib.
The Analyst.
2020 Jul; 145(14):4972-4981. doi:
10.1039/d0an00867b. [PMID: 32515434] - Yiqian Liu, Lianke Liu, Lingxiang Liu, Tongshan Wang, Lian Guo, Yixiang Wang, Zhengzhen Gao, Yongqian Shu. A phase I study investigation of metabolism, and disposition of [14C]-anlotinib after an oral administration in patients with advanced refractory solid tumors.
Cancer chemotherapy and pharmacology.
2020 05; 85(5):907-915. doi:
10.1007/s00280-020-04062-8. [PMID: 32266457] - Aixia Zhang, Bin Liu, Dandan Xu, Yahong Sun. Advanced intrahepatic cholangiocarcinoma treated using anlotinib and microwave ablation: A case report.
Medicine.
2019 Dec; 98(52):e18435. doi:
10.1097/md.0000000000018435. [PMID: 31876723] - Ping Du, Yin Guan, Zhuoling An, Pengfei Li, Lihong Liu. A selective and robust UPLC-MS/MS method for the simultaneous quantitative determination of anlotinib, ceritinib and ibrutinib in rat plasma and its application to a pharmacokinetic study.
The Analyst.
2019 Sep; 144(18):5462-5471. doi:
10.1039/c9an00861f. [PMID: 31380858] - Ai-Ping Zhou, Yuxian Bai, Yan Song, Hong Luo, Xiu-Bao Ren, Xiuwen Wang, Benkang Shi, Cheng Fu, Ying Cheng, Jiyan Liu, Shukui Qin, Jun Li, Hanzhong Li, Xianzhong Bai, Dingwei Ye, Jinwan Wang, Jianhui Ma. Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.
The oncologist.
2019 08; 24(8):e702-e708. doi:
10.1634/theoncologist.2018-0839. [PMID: 30902918] - Jun Lu, Hua Zhong, Tianqing Chu, Xueyan Zhang, Rong Li, Jiayuan Sun, Runbo Zhong, Yuqin Yang, Mohammad Shah Alam, Yuqing Lou, Jianlin Xu, Yanwei Zhang, Jun Wu, Xiaowei Li, Xiaodong Zhao, Kai Li, Liming Lu, Baohui Han. Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy.
The European respiratory journal.
2019 03; 53(3):. doi:
10.1183/13993003.01562-2018. [PMID: 30578392] - Guoshuang Shen, Fangchao Zheng, Dengfeng Ren, Feng Du, Qiuxia Dong, Ziyi Wang, Fuxing Zhao, Raees Ahmad, Jiuda Zhao. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development.
Journal of hematology & oncology.
2018 09; 11(1):120. doi:
10.1186/s13045-018-0664-7. [PMID: 30231931] - Chen-Chun Zhong, Feng Chen, Jun-Ling Yang, Wei-Wei Jia, Li Li, Chen Cheng, Fei-Fei Du, Su-Ping Zhang, Cheng-Ying Xie, Na-Ting Zhang, Olajide E Olaleye, Feng-Qing Wang, Fang Xu, Li-Guang Lou, Dong-Ying Chen, Wei Niu, Chuan Li. Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species.
Acta pharmacologica Sinica.
2018 Jun; 39(6):1048-1063. doi:
10.1038/aps.2017.199. [PMID: 29620050] - Wei Sun, Zhe Wang, Ruimin Chen, Chengke Huang, Rui Sun, Xiaoxia Hu, Wanshu Li, Ruijie Chen. Influences of Anlotinib on Cytochrome P450 Enzymes in Rats Using a Cocktail Method.
BioMed research international.
2017; 2017(?):3619723. doi:
10.1155/2017/3619723. [PMID: 29441353]
